371 completed, 28 terminated, 22 recruiting, 21 unknown. 219 Phase 2, 179 Phase 3, 90 Phase 1, 18 Not applicable, 11 Phase 4.
Follow Vehicle: new trials by email Literature Review of Vehicle trials Research Report on Vehicle
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multicentric, Randomized Study to Assess Safety and Efficacy of Centhaquine in Patients With ARDS Normal Saline, Centhaquine - Acute Respiratory Distress Syndrome (ARDS) | Phase 2 | Not yet recruiting | Pharmazz, Inc. | 80 | 2027-05-01 | 2026-09-17 |
| A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent Normal Saline, Centhaquine - Hypovolemic Shock | Phase 3 | Not yet recruiting | Pharmazz, Inc. | 430 | 2027-02-01 | 2026-09-17 |
| Evaluation of Corneal Endothelium Health Following Articaine Ophthalmic Solution Administration Articaine (CYKLX), Vehicle - Healthy Cornea | Phase 4 | Not yet recruiting | Laboratoires Thea | 165 | 2027-01-01 | 2026-09-24 |
| Study to Determine Efficacy, Safety, and Tolerability of B244 as a Topical Spray in Subjects With Moderate to Severe Acne Vulgaris B244, Vehicle - Acne Vulgaris | Phase 2 | Not yet recruiting | AOBiome LLC | 176 | 2026-10-01 | 2026-10-08 |
| Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free, Vehicle - Ocular Hyperemia | Phase 3 | Recruiting | Alcon Research | 230 | 2026-09-30 | 2026-10-16 |
| An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free, Vehicle - Ocular Hyperemia | Phase 3 | Recruiting | Alcon Research | 178 | 2026-09-27 | 2026-10-16 |
| Phase 2/3 Efficacy and Safety of PP405 in Adult Males PP405 0.05% Topical Gel, Vehicle Topical Gel - Androgenetic Alopecia | Phase 2 / Phase 3 | Recruiting | Pelage Pharmaceuticals, Inc. | 600 | 2026-09-21 | 2026-10-22 |
| Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Cenegermin, Vehicle - Non-Arteritic Anterior Ischemic Optic Neuropathy | Phase 3 | Recruiting | Dompé Farmaceutici S.p.A | 272 | 2026-07-01 | 2026-09-10 |
| An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED Cenegermin, Vehicle - Persistent Corneal Epithelial Defect | Phase 3 | Recruiting | Dompé Farmaceutici S.p.A | 150 | 2026-06-02 | 2026-10-07 |
| Trial of HSK44459 Cream for the Management Plaque Psoriasis HSK44459 Cream, Vehicle - Psoriasis | Phase 1 / Phase 2 | Active not recruiting | Haisco Pharmaceutical Group Co., Ltd. | 180 | 2026-05-22 | 2026-06-08 |
| An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease DFL24498, Vehicle - Dry Eye Disease (DED) | Phase 2 | Recruiting | Dompé Farmaceutici S.p.A | 417 | 2026-05-12 | 2026-10-22 |
| Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III) Total coumarin (TC) cream, Vehicle cream - Psoriasis Vulgaris, Topical Administration | Phase 3 | Recruiting | Psoriasis Research Institute of Guangzhou | 300 | 2026-02-01 | 2026-02-23 |
| Safety and Efficacy of T10430 Eye Drops in Controlling Paediatric Myopia Progression T10430 lower dose, T10430 middle dose, T10430 higher dose - Myopia | Phase 2 | Recruiting | Laboratoires Thea | 200 | 2026-01-21 | 2026-04-13 |
| Effects of Sweetener Consumption on Risk Factors for Heart Disease in Prediabetic Subjects Saccharin, Sucralose, Erythritol - Prediabetic State, Metabolic Syndrome | Not applicable | Not yet recruiting | Charite University, Berlin, Germany | 80 | 2026-01-05 | 2026-01-29 |
| Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) VP-102, Vehicle - Common Warts, Common Warts (Verruca Vulgaris) | Phase 3 | Recruiting | Verrica Pharmaceuticals Inc. | 300 | 2025-12-17 | 2026-01-21 |
| Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE) lotilaner, Vehicle - Ocular Rosacea | Phase 2 | Enrolling by invitation | Tarsus Pharmaceuticals, Inc. | 155 | 2025-12-05 | 2026-03-02 |
| A Study to Evaluate AI-09 In Participants With Glabellar Lines AI-09 Ready Use Injectable Botulinum Toxin, Vehicle - Glabellar Lines | Phase 2 | Active not recruiting | Eirion Therapeutics Inc. | 68 | 2025-12-03 | 2026-01-07 |
| An Efficacy and Safety Study of DFL24498 in the Treatment of AKC DFL24498, Vehicle, dexamethasone sodium phosphate (DSP) ophthalmic solution - Atopic Keratoconjunctivitis | Phase 3 | Recruiting | Dompé Farmaceutici S.p.A | 153 | 2025-12-01 | 2026-09-21 |
| Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%, Vehicle, Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E. - Actinic Keratosis | Phase 3 | Recruiting | Sun Pharmaceutical Industries, Inc. | 260 | 2025-11-29 | 2026-04-22 |
| A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray 0.5% VVN432 Nasal Spray, 1% VVN432 Nasal Spray, Vehicle - Chronic Rhinosinusitis (CRS) | Phase 1 | Recruiting | VivaVision Biotech, Inc | 60 | 2025-11-06 | 2025-12-02 |
Showing 20 of 478. Sign in to see all of them.
Acne Vulgaris (47) · Dry Eye Syndromes (40) · Dermatitis, Atopic (32) · Presbyopia (18) · Psoriasis (18) · Rosacea (16) · Conjunctivitis, Allergic (13) · Glaucoma, Open-Angle (12) · Inflammation (12) · Ocular Hypertension (12) · Pain (11) · Cataract (10) · Eczema (10) · Keratosis, Actinic (10) · Osteoarthritis, Knee (9)
Sun Pharmaceutical Industries, Inc. (29) · Bausch & Lomb Incorporated (22) · Alcon Research (19) · Dompé Farmaceutici S.p.A (14) · Allergan (10) · Pharmazz, Inc. (10) · Bausch Health Americas, Inc. (9) · Novan, Inc. (8) · Omeros Corporation (8) · AOBiome LLC (7) · Biosplice Therapeutics, Inc. (7) · Eirion Therapeutics Inc. (7) · Incyte Corporation (7) · Pfizer (7) · Dow Pharmaceutical Sciences (6)
United States (326) · Canada (42) · Germany (27) · Australia (19) · Spain (18) · Italy (17) · United Kingdom (17) · France (13) · India (13) · Poland (13) · China (12) · Czechia (10) · Japan (10) · Netherlands (8) · Austria (7)
Natalie Yantovskiy (8) · Scott Houston (6) · Anil Gulati (5) · Yusuf Yazici, M.D. (5) · Anya Loncaric (4) · Beth Zib (4) · Zaidoon A. Al-Zubaidy (4) · Anil Gulati, MD, PhD (3) · Anna Chan, PharmD (3)
PMID 41125994, PMID 12424394, PMID 14977340, PMID 20629472, PMID 24935281, PMID 25007364, PMID 27810317, PMID 28670710, PMID 29037354, PMID 30378087, PMID 31111409, PMID 32147881, PMID 32841261, PMID 33428177, PMID 33433785, PMID 36260792, PMID 38216351, PMID 39495154, PMID 40156697, PMID 42192627, PMID 18374301, PMID 18824748, PMID 19049753, PMID 19075138, PMID 19323612, PMID 19393842, PMID 20074751, PMID 20518784, PMID 20851499, PMID 21477426, PMID 22052267, PMID 22435675, PMID 22587791, PMID 22855730, PMID 23169882, PMID 23252768, PMID 23377392, PMID 24255046, PMID 24327173, PMID 24509965, PMID 24703208, PMID 24918567, PMID 25430900, PMID 25504883, PMID 25686388, PMID 25826322, PMID 26159792, PMID 26448169, PMID 26506138, PMID 26580997
2014 (3), 2019 (3), 2025 (3), 2009 (2), 2015 (2), 2017 (1), 2018 (1), R01CA109584 (1), R01EY024966 (1), R03DK078535 (1), U19CA081888 (1), UM1HL087318-06 (1)